Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
50 results about "Pancreatic fibrosis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Copper lowering treatment of inflammatory and fibrotic diseases
InactiveUS6855340B2Treatment safetyLower Level RequirementsBiocideHeavy metal active ingredientsDithiomolybdateLiver disease
The present invention relates generally to the field of prophylaxis and therapy for inflammatory and / or fibrotic diseases which include responses to injuries. In particular, the present invention is related to agents that can bind or complex copper such as thiomolybdate, and to the use of these agents in the prevention and treatment of inflammatory and / or fibrotic diseases. Exemplary thiomolybdates include mono-, di-, tri- and tetrathiomolybdate; these agents are administered to patients to prevent and / or treat inflammatory and / or fibrotic diseases, such as pulmonary disease including pulmonary fibrosis and acute respiratory distress syndrome, liver disease including liver cirrhosis and hepatitis C, kidney disease including renal interstitial fibrosis, scleroderma, cystic fibrosis, pancreatic fibrosis, keloid, secondary fibrosis in the gastrointestinal tract, hypertrophic burn scars, myocardial fibrosis, Alzheimer's disease, retinal detachment inflammation and / or fibrosis resulting after surgery, and graft versus host and host versus graft rejections.
Owner:RGT UNIV OF MICHIGAN
TRAIL receptor agonists for treatment of fibrotic diseases
Pro-apoptotic agents such as ligands and agonists of agonistic TRAIL receptors can induce or increase apoptosis of cells that cause fibrosis and underlying diseases such as liver, pancreatic, lung and skin diseases characterized by fibrosis, cirrhosis, or complications thereof. The compositions and methods can be used to selectively remove activated hepatic stellate cells (HSCs), the originators of liver fibrosis and cirrhosis, and activated pancreatic stellate cells (PSCs), the originators of pancreas fibrosis and pancreatitis, and can be effective to reduce or prevent further chronic fibrosis by simultaneously reducing multiple fibrosis-associated molecules secreted or induced by such activated stellate cells. The compositions are typically effective to target agonistic TRAIL receptors such as TRAIL-R1 / DR4 and TRAIL-R2 / DR5 that are selectively expressed in activated HSCs and PSCs in physiological conditions. Ligands and agonists that can be used to target agonistic TRAIL receptors include, but are not limited to, TRAIL-R1 / DR4 and / or TRAIL-R2 / DR5 agonists.
Owner:B&L DELIPHARM CORP
Method of using rhein for treating fibrotic conditions and tumors
The present invention relates to a method of using an anthraquinone derivative namely 9,10-Dihyro-4,5-dihydroxy-9,10-dioxo-2-anthracenecarboxylic acid, or known as Rhein, for treating chronic pancreatitis induced fibrosis of the pancreas. More particularly, the present invention relates to a method of using Rhein, its derivatives and / or chemical variants as an anti-fibrotic agent. The present invention particularly relates to the suppression of pancreatic stellate cell activation for the management of chronic inflammatory, fibrotic and tumorigenic pathologies in the pancreas.
Owner:HONG KONG BAPTIST UNIV
Application of O-(tetrahydropyrrole) ethyl derivative of cleistanone in preparation of medicines for preventing or treating pancreatic fibrosis
ActiveCN104147019AGood anti-fibrosis effect of pancreasOrganic active ingredientsDigestive systemCleistanoneMedicinal chemistry
The invention relates to the fields of organic synthesis and medicinal chemistry and in particular relates to an O-(tetrahydropyrrole) ethyl derivatives of cleistanone, a preparation method of the O-(tetrahydropyrrole) ethyl derivative of cleistanone as well as application of the O-(tetrahydropyrrole) ethyl derivative of cleistanone in preparation of medicines for preventing or treating pancreatic fibrosis. A novel O-(tetrahydropyrrole) ethyl derivative of the cleistanone is synthesized, and the invention also discloses a preparation method of the O-(tetrahydropyrrole) ethyl derivative. The pharmacology experiment proves that the O-(tetrahydropyrrole) ethyl derivative of the cleistanone has an effect of preventing or treating the pancreatic fibrosis and has the value of developing the medicine for preventing or treating the pancreatic fibrosis.
Owner:JASAN BIO MEDICINE JIAXING CO LTD
Peptides and peptide mimetics to inhibit the onset and/or progression of fibrotic and/or pre-fibrotic pathologies
This invention provides methods of inhibiting the onset or progression of a fibrotic disease (or pre-fibrotic pathology) in a mammal. The method involves administering oen or more peptides (e.g., class A amphipathic helical peptides, G* peptides, etc.) as described herein to a mammal in need thereof, in an amount effective to inhibit the onset and / or progression of the fibrotic disease (or pre-fibrotic condition) in the mammal. In certain embodiments the fibrotic disease is selected from the group consisting of retroperitoneal fibrosis (RPF), hepatic fibrosis and / or chirrhosis, renal fibrosis, and pancreatic fibrosis
Owner:RGT UNIV OF CALIFORNIA
Copper lowering treatment of inflammatory and fibrotic diseases
ActiveUS20050147694A1Treatment safetyLower Level RequirementsBiocideHeavy metal active ingredientsLiver diseaseKidney disease
The present invention relates generally to the field of prophylaxis and therapy for inflammatory and / or fibrotic diseases which include responses to injuries. In particular, the present invention is related to agents that can bind or complex copper such as thiomolybdate, and to the use of these agents in the prevention and treatment of inflammatory and / or fibrotic diseases. Exemplary thiomolybdates include mono-, di-, tri- and tetrathiomolybdate; these agents are administered to patients to prevent and / or treat inflammatory and / or fibrotic diseases, such as pulmonary disease including pulmonary fibrosis and acute respiratory distress syndrome, liver disease including liver cirrhosis and hepatitis C, kidney disease including renal interstitial fibrosis, scleroderma, cystic fibrosis, pancreatic fibrosis, keloid, secondary fibrosis in the gastrointestinal tract, hypertrophic burn scars, myocardial fibrosis, Alzheimer's disease, retinal detachment inflammation and / or fibrosis resulting after surgery, and graft versus host and host versus graft rejections.
Owner:RGT UNIV OF MICHIGAN
Nitrogenous heterocyclic derivatives and their application in drugs
ActiveUS9434695B2Reduce severityOrganic active ingredientsNervous disorderNitrogenous heterocyclic compoundTissue fibrosis
The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.
Owner:SUNSHINE LAKE PHARM CO LTD
Application of caterpillar fungus to preparation of medicine for preventing and/or treating pancreatic fibrosis
ActiveCN105998089AHas anti-pancreatic fibrosis effectHuge social benefitsDigestive systemPlant ingredientsPancreatic fibrosisAqueous extract
The invention relates to the medical use of caterpillar fungus and provides application of caterpillar fungus to preparation of the medicine for preventing and / or treating pancreatic fibrosis. The medicine comprises caterpillar fungus used as an active component and one or more medical auxiliary materials; the caterpillar fungus is selected from natural caterpillar fungus, caterpillar fungus fermentation mycelia and an extract of natural caterpillar fungus and caterpillar fungus fermentation mycelia; the extract is selected from one or combination of a water extract, an alcohol extract, an ester extract, an ether extract and a chloroform extract. Through experiments, the influence of caterpillar fungus on rat pancreatic fibrosis is observed; the experiment shows that the caterpillar fungus has an effect of resisting pancreatic fibrosis; therefore, the caterpillar fungus can be used as the active component for preparing the medicine for resisting pancreatic fibrosis and is high in social benefit and research value.
Owner:青海珠峰冬虫夏草工程技术研究有限公司
Method for ameliorating fibrosis using 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea
The present invention provides an application of 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea in preparation of drugs for treating and reducing a fibrotic disease. The fibrotic disease is skin sclerosis, cardiac fibrosis, pulmonary fibrosis, hepatic fibrosis, pancreatic fibrosis, or renal fibrosis.
![Method for ameliorating fibrosis using 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea](https://images-eureka.patsnap.com/patent_img/8ca0833b-f9f9-4e6f-b27d-eae16bc03e76/US20200016100A1-D00001.png "Method for ameliorating fibrosis using 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea")
![Method for ameliorating fibrosis using 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea](https://images-eureka.patsnap.com/patent_img/8ca0833b-f9f9-4e6f-b27d-eae16bc03e76/US20200016100A1-D00002.png "Method for ameliorating fibrosis using 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea")
![Method for ameliorating fibrosis using 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea](https://images-eureka.patsnap.com/patent_img/8ca0833b-f9f9-4e6f-b27d-eae16bc03e76/US20200016100A1-D00003.png "Method for ameliorating fibrosis using 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea")
Owner:CHEN KUEN FENG +1
Copper lowering treatment of inflammatory and fibrotic diseases
InactiveUS20070248689A1Treatment safetyLower Level RequirementsHeavy metal active ingredientsBiocideKidney diseaseLiver disease
The present invention relates generally to the field of prophylaxis and therapy for inflammatory and / or fibrotic diseases which include responses to injuries. In particular, the present invention is related to agents that can bind or complex copper such as thiomolybdate and thiotungstate, and to the use of these agents in the prevention and treatment of inflammatory and / or fibrotic diseases. Exemplary thiomolybdates include mono-, di-, tri- and tetrathiomolybdate wherein exemplary thiotungstates include mono-, di-, tri-. And tetrathiotungstate; these agents are administered to patients to prevent and / or treat inflammatory and / or fibrotic diseases, such as pulmonary disease including pulmonary fibrosis and acute respiratory distress syndrome, liver disease including liver cirrhosis and hepatitis C, kidney disease including renal interstitial fibrosis, scleroderma, cystic fibrosis, pancreatic fibrosis, keloid, secondary fibrosis in the gastrointestinal tract, hypertrophic burn scars, myocardial fibrosis, Alzheimer's disease, retinal detachment inflammation and / or fibrosis resulting after surgery, and graft versus host and host versus graft rejections.
Owner:RGT UNIV OF MICHIGAN
Novel therapeutic use of polypodium extracts
InactiveUS20060093690A1Prevention and therapyReduce adverse effectsBiocideMuscular disorderBone marrow fibrosisCardiac fibrosis
New therapeutic use of Polypodium extract. A new use of Polypodacea genus extracts is described for the treatment of fibrotic pathologies, such as, scleroderma, pulmonary fibrosis, atherosclerosis, bone marrow fibrosis, liver fibrosis, pancreatic fibrosis, kidney fibrosis, cardiac fibrosis, Dupuytrem's disease and, specially, Peyronie's disease; said fibrotic pathologies are produced by an extracellular matriz (ECM) overexpresion, and by a Transforming Growth Factor (TFG-β) overexpression. It is disclosed extracellular matriz inhibition in vitro; and penis tunica albuginea reduction and plaque redution in patients who suffer Peyronie's diseaseas after Polypodium extracts administration. In a preferred mode, Polypodium extracts are obtained from Polypodium leucotomos rhizomes and extraction with a polar solvent.
Owner:ESPECIALIDADES FARMS CENT
Applications of cleistanone O-(benzimidazolyl) ethyl derivative in preparation of drugs for preventing or treating pancreatic fibrosis
InactiveCN104825466AGood anti-fibrosis effect of pancreasOrganic active ingredientsDigestive systemMedicineCleistanone
The invention relates to the fields of organic synthesis and pharmaceutical chemistry, and specifically relates to a cleistanone O-(benzimidazolyl) ethyl derivative, a preparation method thereof, and applications of the cleistanone O-(benzimidazolyl) ethyl derivative in the preparation of drugs for preventing or treating pancreatic fibrosis. A novel cleistanone O-(benzimidazolyl) ethyl derivative is synthesized, and a preparation method thereof is disclosed. Pharmacology experiment results show that the provided cleistanone O-(benzimidazolyl) ethyl derivative has an effect on preventing or treating pancreatic fibrosis, and thus the cleistanone O-(benzimidazolyl) ethyl derivative is advantageously used to produce drugs for preventing or treating pancreatic fibrosis.
Owner:NANJING GUANGKANGXIE BIOLOGICAL MEDICAL TECH
Application of O-(1H-tetrazole) ethyl derivative of cleistanone to preparing drug for preventing or treating pancreatic fibrosis
InactiveCN104739846AGood anti-fibrosis effect of pancreasOrganic active ingredientsDigestive systemCleistanone1H-tetrazole
The invention relates to the fields of organic synthesis and medicinal chemistry, and relates to O-(1H-tetrazole) ethyl derivative of cleistanone, a preparation method thereof and an application thereof to preparing a drug for preventing or treating pancreatic fibrosis. The invention synthesizes a novel O-(1H-tetrazole) ethyl derivative of cleistanone and discloses a preparation method of the novel O-(1H-tetrazole) ethyl derivative. According to the pharmacology experiments, the O-(1H-tetrazole) ethyl derivative of cleistanone has the effect of preventing or treating pancreatic fibrosis, and has a value of developing a drug for preventing or treating pancreatic fibrosis.
Owner:NANJING UNIV
Application of cationic polymer in preparation of drugs for removing intestinal microbial toxins and treating tumors
ActiveCN114099540AGrowth inhibitionInhibit transferOrganic active ingredientsMetabolism disorderMetaboliteIntestinal microorganisms
The invention relates to the field of medicines, in particular to application of a cationic polymer in preparation of medicines for treating or preventing tumors. By oral administration of the cationic polymer, various cancers can be relieved, treated and prevented, and complications of the cancers can be relieved. By oral administration of the cationic polymer, metabolites generated by intestinal microorganisms can be effectively removed or eliminated, endotoxin generated by bacteria can be removed, endotoxin entering blood can be reduced, bacterial CpG-DNA entering blood can be reduced, and bacterial flagellin entering blood can be reduced. The preparation can reduce systemic inflammation of a human body and inflammation of a tumor environment, can improve a tumor immune environment, activates cell autophagy to inhibit growth and metastasis of tumors, and reduces tissue fibrosis including liver cirrhosis and pancreatic fibrosis. The cationic polymer which is not decomposed and absorbed by the digestive tract can also be used in combination with other anti-tumor therapies; the traditional Chinese medicine composition is combined with radiotherapy, chemotherapy and immunotherapy to improve the curative effect and tolerance.
Owner:SQ BIOPHARMA INC
New application of guava leaves and total flavones of guava leaves
ActiveCN108619245ASimple extraction methodThe detection method is simpleDigestive systemPlant ingredientsSide effectActive component
The invention relates to application of total flavones of guava leaves in preparation of drugs for prevention and treatment of pancreatitis. The invention further provides a pharmaceutical compositionfor prevention and treatment of pancreatitis. The pharmaceutical composition comprises an effective therapeutic dose of total flavones of guava leaves as an active component and a pharmaceutically acceptable carrier. Animal experiments show that the total flavones of the guava leaves can inhibit the excessive proliferation of pancreatic stellate cells and alleviate the degree of pancreatic fibrosis by inhibiting the activation of the P2X7R-mediated NLRP3 inflammation signal pathway, have good effects on prevention and treatment of pancreatitis, have no toxic and side effects and can be used for preparing drugs for prevention and treatment of pancreatitis.
Owner:天津市医药科学研究所
Composition and application thereof in medicine for preventing or treating pancreatic fibrosis
The invention relates to the fields of organic synthesis and medicinal chemistry, in particular to a composition, a preparation method, and application of the composition in preparation of medicine for preventing or treating pancreatic fibrosis. The invention discloses the composition and the preparation method thereof. A pharmacological experiment shows that the composition has the effect of preventing or treating pancreatic fibrosis, and has the value for developing medicine for preventing or treating pancreatic fibrosis.
Owner:南京海澳斯生物医药科技有限公司
Copper lowering treatment of inflammatory and fibrotic diseases
InactiveUS20070298122A1Treatment safetyLower Level RequirementsHeavy metal active ingredientsBiocideLiver diseaseKidney disease
The present invention relates generally to the field of prophylaxis and therapy for inflammatory and / or fibrotic diseases which include responses to injuries. In particular, the present invention is related to agents that can bind or complex copper such as thiomolybdate, and to the use of these agents in the prevention and treatment of inflammatory and / or fibrotic diseases. Exemplary thiomolybdates include mono-, di-, tri- and tetrathiomolybdate; these agents are administered to patients to prevent and / or treat inflammatory and / or fibrotic diseases, such as pulmonary disease including pulmonary fibrosis and acute respiratory distress syndrome, liver disease including liver cirrhosis and hepatitis C, kidney disease including renal interstitial fibrosis, scleroderma, cystic fibrosis, pancreatic fibrosis, keloid, secondary fibrosis in the gastrointestinal tract, hypertrophic burn scars, myocardial fibrosis, Alzheimer's disease, retinal detachment inflammation and / or fibrosis resulting after surgery, and graft versus host and host versus graft rejections.
Owner:BREWER GEORGE J
Traditional Chinese medicine formula for preventing pancreatic fibrosis, and preparation method thereof
InactiveCN110179886APrevent fibrosisPromote absorptionAnthropod material medical ingredientsMetabolism disorderSide effectImmune complex deposition
The present invention belongs to the technical field of traditional Chinese medicines and discloses a traditional Chinese medicine formula for preventing pancreatic fibrosis. The traditional Chinese medicine formula comprises ground beeltles, leeches, white grubs, gadflies, semen armeniacae amarae, Chinese rhubarb, peach kernels, radix scutellariae, rhizoma rehmanniae, radix paeoniae alba, licorice, resina toxicodendri, radix salviae miltiorrhizae and cordyceps sinensis mycelia. The present invention also discloses a preparation method of the traditional Chinese medicine formula for preventingthe pancreatic fibrosis. Medicine weighing according to the formula, medicine drying, stirring and crushing, Chinese rhubarb decocting, mixing, pill manufacturing, etc. are conducted to prepare a finished product of water pills. The formula can lower blood sugar, can also treat low-grade inflammation of diabetes metabolism, simultaneously removes immune complexes and repairs islet cells, so as toprevent the pancreatic fibrosis. The preparation method prepares the formula into the water pills which are beneficial to absorption of active ingredients of the medicines and thus achieve an effectof rapid onset. The traditional Chinese medicine formula is free of toxic and side effects and suitable for use.
Owner:广东新创南方医疗科技有限公司
Method of using dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants in treatments of fibrotic and diabetic conditions
A polyphenol derivative of the stilbenoid family, namely trans-3,5,4′-trihydroxybibenzyl, also known as dihydro-resveratrol, is disclosed as a remedial agent. In particular, the usage of dihydro-resveratrol as an anti-fibrotic agent in suppressing the activation of pancreatic stellate cells (PSCs) is presented. One embodiment also relates to the management of pancreatic fibrosis, which is often accompanied with chronic pancreatitis and desmoplastic reaction of pancreatic cancer. Another embodiment has applications in preventing or alleviating or treating pancreatic cancer or pancreatogenic diabetes.
Owner:HONG KONG BAPTIST UNIV
Method for ameliorating fibrosis using 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea
The present invention provides an application of 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea in preparation of drugs for treating and reducing a fibrotic disease. The fibrotic disease is skin sclerosis, cardiac fibrosis, pulmonary fibrosis, hepatic fibrosis, pancreatic fibrosis, or renal fibrosis.
![Method for ameliorating fibrosis using 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea](https://images-eureka.patsnap.com/patent_img/00b35c95-7282-4f78-8ce7-b9b99cfc0450/US10993923-D00001.png "Method for ameliorating fibrosis using 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea")
![Method for ameliorating fibrosis using 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea](https://images-eureka.patsnap.com/patent_img/00b35c95-7282-4f78-8ce7-b9b99cfc0450/US10993923-D00002.png "Method for ameliorating fibrosis using 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea")
![Method for ameliorating fibrosis using 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea](https://images-eureka.patsnap.com/patent_img/00b35c95-7282-4f78-8ce7-b9b99cfc0450/US10993923-D00003.png "Method for ameliorating fibrosis using 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea")
Owner:CHEN KUEN FENG +1
Application of Akkermansia muciniphila in the aspect of treating chronic pancreatitis
ActiveCN112933115AReduce fibrosisDamage reliefAntipyreticDigestive systemProinflammatory cytokineCytokine
The invention discloses application of Akkermansia muciniphila in the aspect of treating chronic pancreatitis, and belongs to the application field of probiotics. The invention provides the application of an Akkermansia muciniphila BAA-835 strain in preparation of a product for treating chronic pancreatitis, and the strain can relieve pancreatic atrophy symptoms, acinus cell injury and inflammation infiltration, reduce release of proinflammatory cytokines and infiltration of macrophages, relieve pancreatic fibrosis degree in an active state or an inactive state, improve pancreatic fibrosis resistance and improve pancreatic fibrosis resistance. The compound can be used for preparing medicines, pharmaceutical compositions, functional foods and feeds for treating chronic pancreatitis, and has a wide application prospect.
Owner:JIANGNAN UNIV
Application of piperazinyl and dihydroxy ethylamino derivative composition of Atropurpuran to prevention and treatment of pancreatic fibrosis
Owner:NANJING FUHAIAOSAI PHARMA CO LTD
Application of Cordyceps sinensis in the preparation of drugs for preventing and/or treating pancreatic fibrosis
ActiveCN105998089BHas anti-pancreatic fibrosis effectDigestive systemPlant ingredientsBiotechnologyRat Pancreas
Owner:青海珠峰冬虫夏草工程技术研究有限公司
Composition and application thereof to medicines for preventing or treating pancreatic fibrosis
The invention relates to the field of organic synthesis and medicinal chemistry and in particular relates to a composition, a preparation method and an application of the composition to preparation of medicines for preventing or treating pancreatic fibrosis. The invention discloses the composition and the preparation method thereof. Pharmacological experiments show that the composition has the function of preventing or treating pancreatic fibrosis and has the value in developing the medicines for preventing or treating pancreatic fibrosis.
Owner:苏州贺澳德生物医药科技有限公司
Application of sodium tanshinone IIA sulfonate in preparation of anti-pancreatic fibrosis medicine
The invention relates to the technical field of medicines, in particular to application of sodium tanshinone IIA sulfonate in preparation of a medicine for resisting pancreatic fibrosis. The application has the advantages that a novel medical application is provided for the prescription medicine tanshinone IIA sodium sulfonate, and a novel clinical treatment means is provided for pancreatic fibrosis.
Owner:中国人民解放军海军军医大学第一附属医院
Composition and application thereof in drugs for preventing or treating pancreatic fibrosis
The invention relates to the field of organic synthesis and pharmaceutical chemistry, in particular to a composition 82092202050618, a preparation method and use of the composition 82092202050618 in preparation of drugs for preventing or treating pancreatic fibrosis. The invention discloses a composition 82092202050618 and a preparation method thereof. A pharmacology experiment shows that the composition 82092202050618 has an effect of preventing or treating pancreatic fibrosis, and has value of development of the drugs for preventing or treating pancreatic fibrosis.
Owner:NANJING UNIV
Use of vitamin b2 in the preparation of medicines for preventing and treating fibrotic diseases
ActiveCN109602748BInhibition of pathological processesOrganic active ingredientsSenses disorderBone marrow fibrosisCardiac fibrosis
Owner:SHENYANG PHARMA UNIVERSITY
Application of composition of O-(diethylamino)ethyl derivative and O-(piperazinyl)ethyl derivative of Harrisotone A in pancreatic fibrosis preventing or treating drugs
The invention relates to the field of organic synthesis and medicinal chemistry and particularly relates to a composition, a preparation method and an application of the composition in preparing pancreatic fibrosis preventing or treating drugs. The invention discloses the composition and the preparation method thereof. Pharmacological experiments indicate that the composition provided by the invention has an effect of preventing or treating pancreatic fibrosis and a value in developing pancreatic fibrosis preventing or treating drugs.
Owner:NANJING GUANGKANGXIE BIOLOGICAL MEDICAL TECH
Composition and application thereof to medicines for preventing or treating pancreatic fibrosis
InactiveCN105287555ADigestive systemHeterocyclic compound active ingredientsOrganic synthesisPancreatic fibrosis
The invention relates to the field of organic synthesis and medicinal chemistry and in particular relates to a composition, a preparation method and an application of the composition to preparation of medicines for preventing or treating pancreatic fibrosis. The invention discloses the composition and the preparation method thereof. Pharmacological experiments show that the composition has the function of preventing or treating pancreatic fibrosis and has the value in developing the medicines for preventing or treating pancreatic fibrosis.
Owner:NANJING FUHAIAOSAI PHARMA CO LTD
Composition and application thereof in drug for preventing or treating pancreatic fibrosis
The invention relates to the fields of organic synthesis and medicinal chemistry, and in particular relates to a composition, a preparation method and application of the composition in preparing a drug for preventing or treating pancreatic fibrosis. The invention discloses a composition and a preparation method thereof. Based upon pharmacological experiments, the composition disclosed by the invention has an effect on preventing or treating the pancreatic fibrosis, so that the composition has the value of developing the drug for preventing or treating the pancreatic fibrosis.
Owner:南京海澳斯生物医药科技有限公司
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com